<DOC>
	<DOCNO>NCT00335985</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial carry assess efficacy GB-0998 treatment steroid-resistant polymyositis dermatomyositis base change manual muscle strength ( MMT ) score primary endpoint , addition , assess safety GB-0998 .</brief_summary>
	<brief_title>Efficacy Safety Study GB-0998 Treatment Steroid-resistant Polymyositis Dermatomyositis ( PM/DM )</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients define `` definite '' base criterion Bohan Peter polymyositis dermatomyositis . Patients define steroidresistant one base change score manual muscle test ( MMT ) serum level creatine kinase ( CK ) observation period administration drug . Patients malignant tumor . Patients acute interstitial pneumonia , include acute exacerbation chronic . Patients severe muscular atrophy long period . Patients severe infectious disease . Patients anamnesis shock hypersensitivity drug . Patients severe hepatic disorder severe renal disorder . Patients anamnesis cerebral infarction ischemic heart disease , symptom disease . Patients diagnose IgA deficiency past history . Pregnant , lactating , probably pregnant patient , patient want become pregnant . Patients administer immunoglobulin dosage within 6 week consent .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>polymyositis , dermatomyositis</keyword>
	<keyword>High-dose intravenous immunoglobulin</keyword>
	<keyword>Venoglobulin-IH</keyword>
	<keyword>Steroid-resistant polymyositis ( PM ) dermatomyositis ( DM )</keyword>
</DOC>